biostax jkb-122:景凱
景凱
2023年4月21日—一、本公司於111年9月29日與Biostax簽訂新藥JKB-122獨家授權產品臨床開發與經銷.合約,關於簽約金部份,約定Biostax支付美金50萬元及股票25萬股予本 ...。其他文章還包含有:「BiostaxCorpAnnouncesFDAAcceptanceofThree...」、「BiostaxCorpAnnouncestheFDAsAcceptanceofThree」、「BiostaxCorpAnnouncestheFDAsAcceptanceofThree...」、「Biostax–TLR4JKB」、「ImmuneTherapeutics」、「JKB」、「新聞內容-BE6...
查看更多 離開網站Biostax Corp Announces FDA Acceptance of Three ...
https://drug-dev.com
Biostax Corp Announces FDA Acceptance of Three Investigational New Drug Applications Transfers for JKB-122 for the Treatment of NASH, NAFLD, and AIH.
Biostax Corp Announces the FDAs Acceptance of Three
https://www.globenewswire.com
Biostax Corp Announces the FDAs Acceptance of Three Investigational New Drug Applications (IND) Transfers for JKB-122 for the Treatment of NASH, ...
Biostax Corp Announces the FDAs Acceptance of Three ...
https://www.biostaxcorp.com
Biostax Corp Announces the FDAs Acceptance of Three Investigational New Drug Applications (IND) Transfers for JKB-122 for the Treatment of ...
Biostax – TLR4 JKB
https://www.biostaxcorp.com
JKB-122 is a small molecule and a long-acting TLR4 antagonist. This drug has demonstrated in preclinical models anti-fibrotic, immuno-modulating, ...
Immune Therapeutics
https://www.biostaxcorp.com
Biostax Corp. · Biostax Corp Announces the FDAs Acceptance of Three Investigational New Drug Applications (IND) Transfers for JKB-122 for the Treatment of NASH, ...
JKB
https://www.taiwanj.com
JKB-122在活體動物試驗中證實可以改善自體免疫性肝炎(AIH),降低ALT以及AST,也抑制肝臟中促進發炎的相關因子IFN-γ, IL-1β, IL-5, IL-6以及TNF-α。JKB-122在2015年初獲得 ...
新聞內容-BE63B4B6-39CF-4956
http://just2.entrust.com.tw
一、本公司於111年9月29日與Biostax簽訂新藥JKB-122獨家授權產品臨床開發與經銷合約,關於簽約金部份,約定Biostax支付美金50萬元及股票25萬股予本公司。 · 二、此簽約金延 ...
景凱(6549)合作夥伴Immune Therapeutics(已更名為Biostax ...
https://news.gbimonthly.com
一、本公司於111年9月29日與Biostax簽訂新藥JKB-122獨家授權產品臨床開發與經銷合約,關於簽約金部份,約定Biostax支付美金50萬元及股票25萬股予本 ...
景凱:合作夥伴Biostax簽訂新藥JKB
https://www.moneydj.com
一、本公司於111年9月29日與Biostax簽訂新藥JKB-122獨家授權產品臨床開發與經銷合約,關於簽約金部份,約定Biostax支付美金50萬元及股票25萬股予本 ...